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ABSTRACT 
Among patients with resistant hyperten-
sion, it is very important to select patients 
most likely to benefit from renal sympa-
thetic denervation, because they represent 
a very mixed group of diagnoses. 
Prior to diagnosing a patient as having 
resistant hypertension, it is important to 
document adherence and exclude white-
coat hypertension, inaccurate measure-
ments of blood pressure and secondary 
causes of hypertension. 
Renal sympathetic denervation has been 
demonstrated as an antihypertensive treat-
ment in resistant hypertension patients 
with additional positive effects on glucose 
metabolism and insulin sensitivity in type 
2 diabetes. 
We report a single centre report of renal 
sympathetic denervation effects in a small 
cohort of patients with resistant hyperten-
sion and stage 2-3 chronic kidney disease. 
Blood pressure reduction after renal sym-
pathetic denervation was sustained at con-
secutive follow-up visits one, three and six 
months when compared to the baseline: 
office systolic blood pressure was signifi-
cantly lower (144 ± 13, 140 ± 17, 141 ± 15 
mmHg, p<0.001). 
Randomized clinical trials are required to 
assess the impact of the reported changes. 
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INTRODUCTION
Resistant hypertension is defined as blood 
pressure that remains above 140/90 mmHg 
despite the continuous use of three antihy-
pertensive agents in optimal dose, includ-
ing diuretic and lifestyle changes. Resistant 
hypertension is associated with a hyper-
active sympathetic nervous system and 
directly linked with a high risk of target 
organ damage. (1, 2) 
Increased activation of the sympathetic 
nervous system (SNS) is identified as an 
important factor in the development and 
progression of resistant hypertension 
(RH), a condition that confers a high car-
diovascular risk to the patient due to both 
persistent blood pressure elevation and the 
high prevalence of comorbidities and or-
gan damage. (3, 4) 
Among patients with resistant hyperten-
sion, it is very important to select patients 
most likely benefit from renal sympathetic 
denervation, because patients with resist-
ant hypertension represent a very mixed 
group of diagnoses. Chronic kidney dis-
ease is responsible for sympathetic nervous 
system hyperactivation that leads to fluid 
overload, aggravation of hypertension 
and further deterioration and loss of renal 
function. (3 - 5) 
Despite the available pharmacological 
inhibition of the sympathetic nervous 
system, pharmacotherapy does not pro-
vide adequate effects in clinical practice. 
Therefore, renal sympathetic denervation 
(RDN), which produces multilevel inhi-
bition of the sympathetic nervous system 
that triggers additional positive effects on 
glucose metabolism and insulin sensitivity, 
could be a therapeutic option for treating 
resistant hypertension. (5)
MATERIALS AND METHODS
The medical histories of 100 patients with 
resistant hypertension (from the Hospital 
Merkur Register) include documentation 
on duration, severity and progression of 
the hypertension; treatment adherence; re-
sponse to prior medications, including ad-
verse events; as well as current medication 
use, including herbal and over-the-counter 
medications. A biochemical evaluation of 
treatment-resistant hypertensive patients 
includes a routine metabolic profile (sodi-
um, potassium, chloride, bicarbonate, glu-
cose, blood urea nitrogen and creatinine) 
and urinalysis. The evaluation includes 
regular blood pressure measurements, a 
physical examination, and non-invasive/
invasive imaging. Before the RDN inter-
vention antihypertensive treatment was 
optimized (BHS/NICE treatment algo-
rithm), non-concordance with pharmaco-
therapy and secondary forms of hyperten-
sion were excluded.
Among 100 patients with resistant hyper-
tension, we select patients (in stepwise 
screening protocol, multidisciplinary 
meeting) that were most likely to ben-
efit from Renal sympathetic denervation 
(RDN). The RDN method and its risks and 
benefits were explained to 7 patients, and 
written consent was obtained. The study 
was approved by the local ethics commit-
tee and patients provided written informed 
consent to participate.
In our Centre, RDN was performed using 
standard radiofrequency system with ab-
lation catheter (5F system/6F guide cath-
eter; SymplicityTM RDN System) inserted 
through the femoral artery, engaging the 
renal artery bilaterally. 
Five to six nerve ablations of 100 second 
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duration on each side were performed 
without any complications. 
Blood pressure measurements at one, three 
and six month follow-up visits were com-
pared to baseline values. We used STATIS-




From 100 patients referred due to resist-
ant hypertension, more than two-thirds of 
the patients (76%) did not meet the criteria 
of refractory resistant, or had a secondary 
form of hypertension (17%). 
Only seven patients with resistant hyper-
tension (7%) met the criteria for RDN: at 
baseline 2M/5F, values were 62 ± 6 years, 
184/106 ± 21/26 mmHg, 6.7 ± 1 for num-
ber of antihypertensive drug classes (diu-
retic, angiotensin-converting enzyme in-
hibitor or angiotensin receptor blocker, 
calcium channel blocker, direct vasodilator 
(urapidil), beta blockers, centrally acting 
sympatholytic (moxonidine), aldosterone 
antagonist (spironolactone), minoksidil), 
statin therapy and in 50 % of patients oral 
hypoglicemic drugs. 
At one, three and six months after the 
procedure, office systolic BPs were sig-
nificantly lower (144 ± 13, 140 ± 17, 141 
± 15 mmHg, p<0.001). Six months after 
the procedure the number of antihyper-
tensive drug classes required was 6.5 ±1, 
with proteinuria amelioration in patients 
with type 2 diabetes and diabetic nephopa-
thy (2 from 4 with DM) and stable chronic 
kidney disease (eGFR-MDRD: CKD stage 
2 in 5F, CKD stage 3 in 2 M), without wors-
ening of renal function. The office systolic 
blood pressure (BP) reduction after RDN 
was sustained at consecutive follow-up vis-
its over 12 months when compared to the 
baseline. 
The ABPM revealed hypertension with 
non-dipping BP pattern before RDN in 
50% of patients. Blood pressure (BP) re-
duction after RDN was a 9 and 10% reduc-
tion of ABPM (sustained at follow-up vis-
its three and six months compared to the 
baseline). The RDN restored the dipping 
BP pattern. An additional positive effect 
was observed on proteinuria alleviation 
(UAE) in two patients: after the procedure 
UAE was 7.9 mg/mmol in the first patient 
(before RDN, 8.3), and 30 mg/mmol in the 
second patient (before RDN, 400) with sta-
bile values of HbA1c (6.5 and 6.9 %).
DISCUSSION
Resistant hypertension is still unrecog-
nized as a diagnosis and insufficiently 
researched. (1, 2) Because of diagnostic 
procedure complexity, both doctor and pa-
tient motivation can be absent. Although 
the most common causes of therapeutic 
failure are undiscovered secondary causes 
of hypertension and lack of patient compli-
ance, in about 10% of cases it can be attrib-
uted to resistant hypertension caused by a 
hyperactivity of the sympathetic nervous 
system. (3)
Numerous biological and lifestyle factors 
can contribute to the development of re-
sistant hypertension: medications, volume 
overload, obesity, diabetes mellitus, older 
age, renal parenchymal and renovascular 
disease, primary aldosteronism, obstruc-
tive sleep apnoea, pheochormocytoma, 
Cushing’s syndrome, thyroid diseases, and 
aortic coarctation. (4, 5) 
Renal physiology contributes to circadial 
variability of blood pressure levels. The 
time-related profile of blood pressure lev-
els shows a morning increase and a deeper 
descent during nocturnal rest: a 10-20% 
drop during the night in a healthy subject. 
Patients with secondary hypertension of-
ten display an abnormal circadian blood 
pressure profile, leading to the “non-dip-
per” pattern, requiring different ingestion-
time dependent strategies for therapy of 
hypertension medications. (6, 7)
The resistant hypertension treatment is 
achieved with a nonpharmacological and 
pharmacological approach, treating sec-
ondary hypertension causes and utilizing 
invasive procedures. 
Initial observational studies and our results 
have shown that RDN is a safe and effective 
method of reducing office blood pressure 
in patients with RH, with a positive effect 
on blood glucose regulation, heart and 
kidney function, obstructive sleep apnoea 
and signs of hypertensive end organ dam-
age. (1-3, 5) Even though this method is 
promising, criticism is directed at inade-
quately designed and mostly observational 
studies without 24 hour ambulatory blood 
pressure measurement records, coupled 
with a significant variability in patient re-
sponse to therapy. (8) For these reasons it 
is important to finally assess the effective-
ness of renal denervation and the influence 
it might have on reducing cardiovascular 
morbidity and mortality.
CONCLUSION
Due to potentially beneficial reductions of 
multiple risk factors and safety concerns, 
a focused assessment of already obtained 
data from patients with refractory resist-
ant hypertension after RDN intervention 
should be of importance. 
Patients with type 2 diabetes and CKD 
may be the target population that would 
substantially benefit from RDN. 
Further randomized clinical trials could be 
beneficial in improving both renal and car-
diovascular outcomes.
A multidisciplinary meeting is necessary.
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